Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/23/23
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/23/23
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive CandidiasisBusiness Wire • 03/22/23
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive CandidiasisGlobeNewsWire • 03/22/23
Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies CongressGlobeNewsWire • 03/07/23
Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares in Public Offering of Common StockGlobeNewsWire • 03/07/23
Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred StockGlobeNewsWire • 03/03/23
Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred StockGlobeNewsWire • 03/02/23
Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge ModelGlobeNewsWire • 03/01/23
Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 02/14/23
Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara's CD73 Oncology DFC ProgramGlobeNewsWire • 02/01/23
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive CandidiasisBusiness Wire • 01/25/23
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® PlatformGlobeNewsWire • 01/04/23
Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock SplitGlobeNewsWire • 11/29/22
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The LancetGlobeNewsWire • 11/28/22